Share on StockTwits

Regeneron Pharmaceuticals (NASDAQ:REGN) will release its Q114 earnings data on Thursday, May 8th. Analysts expect Regeneron Pharmaceuticals to post earnings of $0.94 per share and revenue of $609.04 million for the quarter.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings data on Tuesday, February 11th. The company reported $2.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.97 by $1.27. The company had revenue of $610.00 million for the quarter, compared to the consensus estimate of $579.17 million. During the same quarter in the previous year, the company posted $1.47 earnings per share. The company’s revenue for the quarter was up 47.0% on a year-over-year basis. On average, analysts expect Regeneron Pharmaceuticals to post $4.36 EPS for the current fiscal year and $6.88 EPS for the next fiscal year.

Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded down 1.50% on Wednesday, hitting $286.46. The stock had a trading volume of 413,504 shares. Regeneron Pharmaceuticals has a one year low of $206.30 and a one year high of $352.49. The stock has a 50-day moving average of $300.7 and a 200-day moving average of $296.9. The company has a market cap of $28.402 billion and a price-to-earnings ratio of 76.33.

Several analysts have recently commented on the stock. Analysts at Robert W. Baird raised their price target on shares of Regeneron Pharmaceuticals from $362.00 to $368.00 in a research note on Monday. On the ratings front, analysts at Zacks upgraded shares of Regeneron Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note on Wednesday, April 30th. They now have a $359.00 price target on the stock. Finally, analysts at Ned Davis Research upgraded shares of Regeneron Pharmaceuticals from a “sell” rating to a “neutral” rating in a research note on Monday, April 21st. Eight analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $329.73.

Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.